Published: 29 Aug 2025(Updated: 29 Aug 2025)
7 min
7 min read
Neil Renault, Ashley Treas0

From seaweed to scale-up: The journey of IBioIC with INFORS HT fermentation technology

CustomerFood and BeverageMicrobial bioprocessSustainability

The Industrial Biotechnology Innovation Centre (IBioIC) in Scotland supports companies and researchers to address key challenges in biotechnology, from finding new uses for waste to developing sustainable feedstocks. By supporting researchers, startups, and SMEs, IBioIC helps move ideas out of the lab and into real-world applications that contribute to the circular bioeconomy.

Driving industrial biotechnology forward in the UK 

IBioIC is a membership organisation, which plays a central role in helping startups and SMEs move innovative ideas forward through networking, funding, innovation support, skills and access to facilities. A key bottleneck for innovation is the need to demonstrate bioprocesses are saleable from lab-scale. FlexBIO is IBioIC’s open-access bioprocessing scale-up facility, hosted at Heriot-watt University (Edinburgh, Scotland). They are particularly engaged in projects themed around cirular bioeconomy, which involve working with a wide variety of biomasses and feedstocks, from seaweed to seafood waste, food industry by-products, and even waste lithium batteries. By providing access to advanced equipment and facilities, IBioIC supports scaling up processes from lab bench to pilot scale. This type of support is especially important for companies that would not otherwise have the resources to test new technologies or validate processes before taking them to market. 


INFORS HT systems powering scale-up at IBioIC 

Over the years, IBioIC has worked with INFORS HT on several systems including the Labfors 5 solid-state fermenter and most recently the 300 L Techfors pilot-scale bioreactor used for microbial fermentation. 

Their most recent installation was described by Neil Renault, Facility Manager at IBioIC, FlexBIO Facility, as a very positive experience:

“The experience of working with INFORS has been a really good one, from the procurement process through, drafting of P&ID diagrams through the build and attending the factory in Switzerland to see the latter stages. All the way through to delivery. To combine an excellent commissioning and training experience for all involved. INFORS seem to always keep innovating, so there's always subtle differences between the systems which have been implemented following recognised improvements that have been made over previous versions of the same system. This just gives you a sense of the level of experience that they have building this equipment.”

IBioIC also emphasized the importance of support after installation:

“I always say you can never judge equipment manufacturer just on their quote up front, it inevitably all comes down to the support you get after a sale and ongoing support both when you have technical issues but also unique application supports you need. INFORS is a great example of that in terms of the support they will give you.”


From novel feedstocks to waste valorization

The INFORS HT Solid-State Fermenter was funded by Marine Fund Scotland via the Scottish Government. IBioIC saw a real need to work with seaweed as an emerging feedstock. While many people preserve seaweed in acidic fermentations, many high-value products in seaweed do not tolerate those conditions. 

As IBioIC explained:

“Novel fermentations and novel fermentation technologies allow us to work with industry and researchers to scale up novel methods, feedstocks and novel strains of organisms. This type of technology can also be used in a lot of other biomasses. And in particular, in areas of the bioeconomy such as waste valorisation to extract value from a previously discarded waste.”

This approach not only advances research into seaweed but also supports broader goals in sustainable biotechnology, showing how waste streams like seafood by-products or food industry residues can become valuable feedstocks within the circular bioeconomy.

Bridging the gap from lab to pilot scale

The addition of the INFORS HT 300 L Techfors fermenter has expanded IBioIC’s ability to help companies take processes from bench to pilot scale. Their typical pathway moves from shake flasks into 2 L and 30 L stirred-tank fermenters and now into 300 L. INFORS HT worked closely with IBioIC to include features that make the system both flexible and user-friendly: 

  • Additional mass flow controllers (MFCs) and off-gas analysis for more detailed gas handling 
  • Extra impellers for different mixing needs 
  • Redundancy in pH and dissolved oxygen measurements 
  • A power-assisted headplate lift for safe operation 
  • High-level foam sensors and very thorough P&ID diagrams to support troubleshooting

According to IBioIC: 

“This ultimately means we have a very flexible system that can be used on the huge array of projects that we get into our facility for scaling up. In addition, the system is very easy to use. And the user interface also adds a level of confidence and control. Which is what we really need, especially operating within a UK university.” 

For SMEs and startups, this flexibility is critical. IBioIC now has the tools to support projects ranging from expression of novel enzymes to valorisation of complex feedstocks. The new fermenter makes it easier for companies to validate processes, demonstrate commercial potential, and move closer to market readiness.

Building skills and expanding access

Beyond supporting projects, IBioIC also sees its INFORS HT systems as vital tools for training. They deliver CPD courses that range from assembly of small bioreactors to hands-on pilot-scale upstream and downstream processing. 

“The new system from INFORS, benefited by its ease of use, will allow us to work and train others who need to be upskilled in these seldomly taught areas for their own companies benefit.”

This training is part of wider initiatives such as the FlexBIO facility and the RESILIENCE Centre of Excellence for Skills Training in Medicines Manufacturing, both designed to strengthen the UK’s biomanufacturing workforce. The 300 L Techfors fermenter is also central to IBioIC’s open-access pilot facility. Such facilities are rare in the UK and Europe but play an important role in enabling SMEs to access advanced equipment without heavy capital investment. Through the COPILOT Network powered by Pilots4U, IBioIC connects with innovators across Europe, broadening access to pilot-scale capabilities and creating more opportunities for collaboration.

Learn more about the INFORS HT solutions supporting IBioIC

Labfors 5 for solid-state fermentation

Designed for fermentation with non-liquid substrates, enabling innovation with feedstocks such as seaweed.

Learn more

Techfors bioreactor

A pilot-scale system used for fermentation that combines flexibility, scalability, and ease of use for a wide range of biotechnology projects.

Learn more

Labfors 5 for solid-state fermentation

Designed for fermentation with non-liquid substrates, enabling innovation with feedstocks such as seaweed.

Learn more

Techfors bioreactor

A pilot-scale system used for fermentation that combines flexibility, scalability, and ease of use for a wide range of biotechnology projects.

Learn more

Partnering for growth in the bioeconomy 

IBioIC’s partnership with INFORS HT provides the tools, flexibility, and ongoing support needed to scale innovative processes, deliver hands-on training, and strengthen the UK’s position in sustainable biotechnology. By combining cutting-edge equipment with an open-access model, IBioIC is helping innovators unlock new opportunities, transform waste into value, and build the future of the bioeconomy. 

Reach out to IBioIC

Do you need help scaling up a microbial or mammalian project or interested in accessing training to upskill you or your team? Drop them at email at scaleup@ibioic.com or check out IBioIC’s website to learn more about their services and courses.

Are you are working on similar projects or exploring new approaches to fermentation?

Reach out to INFORS HT today by filling out the form below to learn how we can support your experiments and help scale your innovations with our bioreactor technologies.

Did you like this article?Leave us a rating!

1
2
3
4
5
Average: 0/5

Comments(0)

Related articles

Blog
25 Aug 202537 min read4,60
60 stories for 60 years

A legacy of customer-centered excellence: For six decades, INFORS HT has built a legacy rooted in customer commitment, innovation, and lasting partnerships. To celebrate this milestone, we are sharing 60 Stories for 60 Years: a collection of inspiring stories from around the world that highlight the people and moments that define INFORS HT. Explore stories that showcase our people and culture, nemorable moments, growth and innovation, and customer successes, each reflecting our dedication to putting customers first. Join us in celebrating the relationships and breakthroughs that have shaped our journey.

14 Jul 202510 min read4,40
The difference between batch, fed-batch, and continuous processes

Feeding strategy is one of the most influential variables in any bioprocess. Whether you’re working with bacterial, yeast, fungal, or mammalian cell cultures, how you supply nutrients affects everything from growth rates and yields to oxygen demand and product quality. The choice between batch, fed-batch, and continuous culture depends on your organism, application, and production goals. Fortunately, modern bioreactor systems like those from INFORS HT make it easy to implement any of these strategies at lab or pilot scale.

12 Feb 20259 min read1,10
Optimizing HEK293 cell cultures for gene therapy applications: the role of incubator flexibility

Gene therapy is a promising approach for treating various genetic disorders and diseases. A critical component of gene therapy is the production of viral vectors, which serve as delivery vehicles for therapeutic genes. Human Embryonic Kidney 293 (HEK293) cells have become a widely used platform for viral vector production due to their efficiency in transfection and ability to support viral replication. However, optimizing HEK293 cell cultures for large-scale production of viral vectors remains a challenge in making gene therapies more accessible and cost-effective.

25 Aug 202537 min read4,60
60 stories for 60 years

A legacy of customer-centered excellence: For six decades, INFORS HT has built a legacy rooted in customer commitment, innovation, and lasting partnerships. To celebrate this milestone, we are sharing 60 Stories for 60 Years: a collection of inspiring stories from around the world that highlight the people and moments that define INFORS HT. Explore stories that showcase our people and culture, nemorable moments, growth and innovation, and customer successes, each reflecting our dedication to putting customers first. Join us in celebrating the relationships and breakthroughs that have shaped our journey.

14 Jul 202510 min read4,40
The difference between batch, fed-batch, and continuous processes

Feeding strategy is one of the most influential variables in any bioprocess. Whether you’re working with bacterial, yeast, fungal, or mammalian cell cultures, how you supply nutrients affects everything from growth rates and yields to oxygen demand and product quality. The choice between batch, fed-batch, and continuous culture depends on your organism, application, and production goals. Fortunately, modern bioreactor systems like those from INFORS HT make it easy to implement any of these strategies at lab or pilot scale.

12 Feb 20259 min read1,10
Optimizing HEK293 cell cultures for gene therapy applications: the role of incubator flexibility

Gene therapy is a promising approach for treating various genetic disorders and diseases. A critical component of gene therapy is the production of viral vectors, which serve as delivery vehicles for therapeutic genes. Human Embryonic Kidney 293 (HEK293) cells have become a widely used platform for viral vector production due to their efficiency in transfection and ability to support viral replication. However, optimizing HEK293 cell cultures for large-scale production of viral vectors remains a challenge in making gene therapies more accessible and cost-effective.

We care about your privacy

We use cookies to improve user experience. We analyse our traffic, we personalise content and ads on our website, and we provide social media features. Certain cookies are necessary for our website to work properly and to enable you to use its features. With your consent, we also use analytics cookies to improve our website and marketing cookies to display advertisements and content on our website. 
Cookie settings